NovaSure® Endometrial Ablation

Q. What methods of purchase are available for the NovaSure Endometrial Ablation Products?

A. Contact us to be put in touch with a local representative who will be able to provide a quotation and purchasing options available – email: ukgynsurgical@hologic.com

Q. What training support is provided for the NovaSure procedure in my area?

A. Hologic has a team of Clinical Application Specialists dedicated to training and ongoing support for our products. Please contact us to be put in touch with your local team who can provide materials and training support as required: ukgynsurgical@hologic.com

Q. How can I order more NovaSure Patient materials?

A. Additional NovaSure marketing and educational materials are available by contacting us at: ukgynsurgical@hologic.com

Q. What is the shelf life of the NovaSure Advanced device?

A. The Advanced device shelf life is at least 25 months from date of manufacturing. It is Hologic’s policy that NovaSure Advanced devices shall be shipped with a minimum of three month’s shelf life remaining. All NovaSure 3 packs are labeled with a “Use Before” date for easy identification. It is important that devices are not used beyond their expiration date.

Q. Is the NovaSure Disposable Device latex free?

A. Yes, the NovaSure disposable device is latex-free.

Q. Can the NovaSure disposable device be resterilised?

A. The disposable device is a single-use product that is provided sterile to the end user. Re-sterilisation of the device should not be attempted for any reason.

Q. What if I have a disposable device to return that has been opened or used? Is there a process to return of the disposable device?

A. Please contact our technical support team on 0800 032 3318 or your local Hologic representatives who will issue an RMA# for this type of return. In addition, we will ship a biohazard kit for you to ship the used product back to Hologic for sterilisation and evaluation.

Q. What is the life expectancy of the NovaSure controller?

A. The RF Controller was designed for a minimum of 5 years of useful life.

Q. What preventive maintenance and care are required for the NovaSure RF controller?

A. No maintenance is necessary other than regular cleanings, as described in the operator’s manual.

MyoSure® Tissue Removal System

Q. What is the MyoSure Procedure?

A. The MyoSure Tissue Removal System is intended for intrauterine use by trained gynecologists to hysteroscopically resect and remove tissue such as: submucous myomas and endometrial polyps. Learn More

Q. What happens during the MyoSure procedure?

A. The MyoSure procedure is a quick and simple way to remove and resect uterine tissue. In addition, it can be performed in a hospital or outpatient/ambulatory setting. Watch Video

Q. Can the MyoSure system remove large fibroids?

A. Yes. With the MyoSure XL device, the MyoSure system is designed to remove a 5 cm fibroid in 15 minutes or less of cutting time.

Q. What type of distension media should be used with the MyoSure system?

A. The MyoSure system removes pathology via mechanical energy vs. electrical energy and therefore can use saline which is a physiologic distension media. Saline or Ringer’s Lactate, according to BSGE fluid management guidelines, have a higher intravasation safety limit (2500 cc) than is available for non-electrolyte media such as glycine (1000 cc). It should be noted, however, that the MyoSure procedure is compatible with all distension media.1

Q. Can the MyoSure system truly be used with any hysteroscopy pump?

A. Yes, however some pumps have more optimal performance. Any pump which does not have the ability to control flow rate should be considered sub-optimal. Sub-optimal pumps may be adequate for smaller pathology less than 3 cm, but may present distension or visualisation challenges with larger and more complex pathology.

Can we perform the MyoSure procedure in an outpatient/ambulatory setting?

A. Yes, the MyoSure procedure can be performed as an outpatient treatment. Learn More



  1. Miller C, Glazerman L, Roy K, Lukes A. Clinical evaluation of a new hysteroscopic morcellator – Retrospective Case Review. Journal of Clinical Medicine 2(3):163-166, July/August 2009.